Home › Newron Receives Complete Response Letter From US FDA For Xadago (safinamide)
 

Keywords :   


Newron Receives Complete Response Letter From US FDA For Xadago (safinamide)

2016-03-30 07:24:45| drugdiscoveryonline Home Page

Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partners Zambon S.p.A. and US WorldMeds announced recently that a complete response letter from the FDA has been received for safinamide

Tags: complete response letter receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Greece starts six-day working week for some industries
03.07ThaMa-Vet unveils fixed dosage swine syringes
03.07Hurricane Beryl Graphics
03.07Farm Progress America, July 3, 2024
03.07Farm Progress America, July 3, 2024
03.07Digital video subscriptions to reach 3.5 billion by 2028
03.07Hurricane Beryl Forecast Discussion Number 19
03.07Hurricane Beryl Wind Speed Probabilities Number 19
More »